Novartis-Dr Reddy’s Sales Pact, Job Cuts: Are Foreign Firms Altering India Push?
Novartis India To Let Go Of About 400 Employees
Executive Summary
Novartis India hands over sales and distribution of certain established brands, accounting for 50% of the 2020-2021 product revenues, to Dr Reddy’s as more foreign firms opt to leverage ground strengths of local players. Does it represent a wider trend where foreign firms are re-calibrating operations in India to focus energies on specialty and patented products?
You may also be interested in...
BioAsia 2023: Leaders from Novartis, Apple Talk Innovation, Tech, Data Privacy
BioAsia 2023 was a melting pot of ideas with Novartis's CEO and a senior executive from Apple, among others, discussing a range of topics including the potential of novel therapies and platforms such as siRNA and radioligand and also where things were headed as the union of technology and biotech drives new insights into biology and promises to help reimagine healthcare.
Deals, Divestitures In Store As Dr Reddy’s Stays Course To Top Five India League
Investments in differentiated and specialty products and collaborations, alongside divestitures, are part of Dr Reddy’s plans as it seeks to move up the rankings in India. Momentum in China, including an alliance with Sunflower Pharma for orphan diseases, is also being keenly watched.
Deals, Divestitures In Store As Dr Reddy’s Stays Course To Top 5 India League
Investments in differentiated and specialty products and collaborations, alongside divestitures, are part of Dr Reddy’s plans as it seeks to move up the rankings in India. Momentum in China, including an alliance with Sunflower Pharma for orphan diseases, is also being keenly watched.